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Abstract:  The purpose of this study was to clarify the effect of decreased food consumption on evaluation of 
myelotoxicity in routine general toxicity studies.  Male rats were divided into the following 7 groups: 12, 15, and 18 
mg/kg 5-fluorouracil (5-FU) treatment groups (FU12, FU15 and FU18); dietary restriction groups (R12, R15 and R18 
receiving the same amount of food as the rats in the FU12, FU15 and FU18 groups, respectively); and a nontreated 
control group (NT).  We compared the changes in body weight, hematology and the results of cytological analyses of 
bone marrow and histopathology among the groups after administration and recovery periods of 14 and 7 days, 
respectively.  At the end of the administration period, the FU15 and FU18 groups showed decreases in many hematologic 
and bone marrow parameters that were all similar to those in the corresponding dietary restriction groups (R15 and R18). 
A granulocyte abnormality (polyploidy: frequency of 1% or less) was also observed in all 5-FU treated groups.  At the 
end of the recovery period, increases in the reticulocyte and platelet counts and extramedullary hematopoiesis of the 
spleen were observed in the 5-FU treated groups.  These results indicate that the results of general toxicity studies in 
rats should be evaluated in consideration of dietary restriction effects when food consumption is decreased at about 30-
40% or more.  Careful morphological observation of hemocytes would be helpful in distinguishing the effect of a drug 
from that of dietary restriction in relation to hematological and bone marrow parameters.  Performance of a recovery 
test to determine the reactive response of hematopoiesis is also recommended.   (J Toxicol Pathol 2009; 22: 53–63)
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Introduction
In repeated-dose toxicity studies of drugs in rats, weight 
loss and decreased food consumption are often recognized in 
drug administration groups.  Because of this, it is often 
difficult to judge whether the changes in hematology, bone 
marrow examination results or histopathology represent 
direct effects of the drug or indirect effects arising from a 
decrease in food consumption caused by the drug.  It is well 
known that dietary restriction in the rat influences organ 
weights as well as hematologic and blood chemistry 
parameters1–4.  Previous studies have examined the effects of 
decreased food consumption in rats by restricting their diets 
by a constant amount compared with the amount fed to a 
control group, and the results of these studies suggest that 
moderate diet restriction increases longevity4,5.  Diet 
restriction has also been shown to decrease age-related 
development of neoplasia in many organs6.  In long-term 
studies, a moderately restricted diet is useful for examination 
of carcinogenicity because it does not stunt the rat’s growth 
nor influence evaluation of clinical pathology parameters7,8. 
On the other hand, it is necessary to analyze the various 
influences of dietary consumption carefully in toxicity 
studies, where changes of unknown factors are considered to 
appear.  The purpose of the present study was to clarify the 
effects of decreased food consumption on evaluation of 
myelotoxicity in routinely performed general toxicity 
studies.  The anticancer drug 5-fluorouracil (5-FU) belongs 
to the category of chemotherapeutic agents called 
antimetabolites and is a pyrimidine analog9,10.  When it is 
incorporated into the cellular metabolic cycle, cells become 
unable to divide.  In regard to the adverse effects of 5-FU, it 
has been reported to exert cardiotoxicity11,12, gastrointestinal 
toxicity13 and visual toxicity based on its affinity for 
melanin14.  Its developmental toxicity has also been 
studied15,16.  In the present study, we selected 5-FU as a 
positive control drug that causes hematotoxicity, namely, 
bone marrow causes anemia and hemocytopenias based on 
its treatment17–20.  In the present experiment, we set up study 
groups comprising three 5-FU treated groups and three 
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dietary restriction groups receiving food at the same amounts 
as the average intakes of the corresponding 5-FU treated 
groups and analyzed the changes in the results of 
hematology and bone marrow examinations, including 
cytological analysis and histopathology, after an 
administration period of 14 days and recovery period of 7 
days.  Herein, we discuss the toxic effects of 5-FU on the 
hematopoietic organs with special reference to the effects of 
dietary restriction on the hematopoietic system.  We believe 
that the results will provide useful data for toxicity 
assessment of drugs capable of decreasing body weight and/
or food consumption.
Materials and Methods
Animals and housing conditions
Male Crl:CD(SD) rats were obtained from Charles 
River Japan Inc. (Tsukuba, Ibaraki, Japan).  A total of 84 rats 
(12 rats/group) were selected for this study.  Animals were 
housed individually in stainless steel cages (225 mm W ×
350 mm D × 200 mm H) with an artificial lighting cycle of 
12 hours (7:15 to 19:15), temperature of 23 ± 3°C, relative 
humidity of 50% ± 20% and ventilation 10 to 20 times/hour. 
Before group assignment, all animals were allowed free 
access to laboratory animal diet (MF, Oriental Yeast Co., 
Ltd., Tokyo, Japan) and drinking water.  After group 
assignment, the R12, R15 and R18 groups received restricted 
diets.  At the start of dosing / feeding of restricted diets, the 
animals were 6 weeks old.
All animals were treated in accordance with the 
recommendations of the Guide for the Care and Use of 
Laboratory Animals of Taisho Pharmaceutical Co., Ltd.
Study groups
The experimental design is shown in Fig. 1.  The 
animals were divided into the following 7 groups: NT, 
FU12, FU15, FU18, R12, R15 and R18.  The animals in the 
NT group had free access to the diet and were used as the 
nontreated control.  The animals in the FU12, FU15 and 
FU18 groups received oral doses of 12, 15 or 18 mg/kg 5-FU 
(Wako Pure Chemical Industries Ltd., Osaka, Japan) for 14 
consecutive days, respectively.  The dose volume was 10 
mL/kg body weight and was calculated based on the most 
recent body weight.  The animals in the R12, R15 and R18 
groups were not given 5-FU but were placed on a restricted 
diet.  These animals were given amounts of food equivalent 
to that consumed by the rats in the FU12, FU15 and FU18 
groups, respectively.  Diet restriction was started on the next 
day as 5-FU administration.  In the 5-FU treated groups, the 
14 day administration period was followed by a 7 day 
recovery period, which is considered appropriate for 
examination of the reversibility of changes, and the rats did 
not receive 5-FU during this period.
Examinations and methods
Body weight and food consumption were measured 
every day for all animals in the NT and 5-FU treated groups. 
Water intake was measured at three time points (Days 3, 8 
and 13) in the administration period and one point (Day 20) 
in the recovery period (the starting day of administration or 
dietary restriction was designated to be Day 0 of the study). 
The following examinations were performed on all animals, 
except those that died prematurely, at the end of the 
administration (6 rats/group) or recovery period (6 rats/
group).  Animals were fasted for at least 16 hours before 
necropsy, and blood samples were collected via the 
abdominal aorta under ether anesthesia.  EDTA-2K was used 
as the anticoagulant for hematological examination.  The 
following hematological parameters were measured using a 
Technicon H·1E hematology analyzer (Bayer Medical Ltd., 
Tarrytown, NY, USA): red blood cells (RBC), hemoglobin, 
hematocrit, mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), white blood cells 
(WBC), differential WBC absolute counts (lymphocytes, 
neutrophils, eosinophils, monocytes, basophils, and large 
unstained cells [LUC]).  The percentage of reticulocytes was 
measured using an EPICS-XL flow cytometer (Beckman 
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Coulter Inc., Fullerton, CA, USA) with Coriphosphine-O 
stain, and the reticulocyte count was calculated from RBC 
counts and reticulocyte percentage.  The serum 
erythropoietin (EPO) concentration was measured by 
enzyme-linked immunosorbent assay (ELISA) using a 
reagent kit (immunoelit EPO, Toyobo Co., Ltd., Osaka, 
Japan).  After blood sampling, all animals were euthanized 
by exsanguination.  Both femurs were obtained and used for 
evaluation of bone marrow cytology and histopathology. 
The bone marrow nucleated cell count was measured using a 
Techinicon H·1E hematology analyzer (Bayer Medical 
Ltd.).  The cell count was determind by counting 500 cells in 
bone marrow smears stained with May-Grünwald and 
Giemsa.  The absolute count of each type of marrow cell 
(myeloid, erythroid, lymphoid and other cells) was then 
calculated from the marrow cell count and marrow 
differential count data.  The following organs were weighed: 
liver, spleen, kidney, thymus and adrenal, and the ratios of 
these organ weights to body weight (relative weights) were 
calculated based on the final body weight.  For 
histopathological evaluation, the femur (bone marrow), 
liver, spleen, kidney, thymus, adrenal, stomach, duodenum, 
ileum and colon were fixed in 10% neutral buffered 
formalin.  For histopathology, the femur was decalcified by 
the Plank-Rychlo method.  After fixation, hematoxylin and 
eosin (H&E) stained specimens were prepared from paraffin 
blocks and subjected to microscopic observation.
Statistical analysis
Significant differences between the NT and 5-FU 
treated groups or between the NT and dietary restriction 
groups were analyzed according to the following procedures. 
The homogeneity of the variance among the groups was first 
tested by Bartlett’s test.  When the variance was 
demonstrated to be homogeneous, all groups were compared 
by one-way analysis of variance.  When the variance was 
demonstrated to be heterogeneous, the Kruskal-Wallis test 
was employed.  Then Dunnett’s test (if homogeneous) or 
Dunnett’s type multiple comparison test (if heterogeneous) 
was then used if there was a significant difference between 
the groups.
Significant differences between the 5-FU treated and 
dietary restriction groups (such as FU12 vs R12, FU15 vs 
R15, FU18 vs R18) were analyzed according to the 
following procedures.  The homogeneity of the variance 
among the groups was first tested by the F-test, and then the 
Student’s t-test (if homogeneous) or Aspin-Welch’s t-test (if 
heterogeneous) was employed.
Bartlett’s test, one-way analysis of variance, the 
Kruskal-Wallis test and the F-test were conducted with a 
significance level of 5% (two-tailed), and others were 
conducted with significance levels of 1% and 5% (two-
tailed).  Statistical analysis of clinical signs, necropsy or 
histopathology was not performed.
Results
Clinical signs and mortality
There were two premature deaths in the FU18 group 
(one on Day 12 and the other on Day 14).  These animals 
showed lacrimation, loose stools and soiled perineal regions 
before death.  In addition, alopecia was observed in another 
rat in the FU18 group on Day 7.  No abnormalities were 
observed in the dietary restriction groups.  Because of the 
premature deaths, the assessments during the treatment and 
recovery periods, except for the in-life examinations, in the 
Fig. 2. Food consumption changes (A) in the 5-FU treated groups and comparison of body weight (B) in the 5-FU treated and dietary restriction 
groups.56 Evaluation of Myelotoxicity in Rats
FU18 group were only conducted for five animals.
Food consumption and body weight (Fig. 2)
In the 5-FU treated groups, decreases in food 
consumption and/or body weight were observed in the 
animals during the administration period.  The amount of 
food consumption and body weight gain returned to the same 
levels as those in the NT group during the recovery period. 
In the 5-FU treated groups, abnormal feeding behavior 
(eating spilled food) was observed from Day 4 to Day 16 in 
many rats.  Therefore, food consumption in the 5-FU treated 
groups was corrected using the amount of spilled diet.
In the dietary restriction groups, the rats ate all the food 
during the experimental periods.  They ate all food within 
one hour of it being provided from Day 2 onward.  When the 
administration period ended, the ratios of the total amount of 
food consumption for the dietary restricted groups were 
25%, 44% and 53% in the R12, R15, and R18 groups, 
respectively.  The rations 19%, 32% and 41% at the end of 
the recovery period, respectively.  These ratios were 
calculated as following formula: dr / nt -100, where dr
represents the total amount of food consumption in each 
dietary restriction group × 100 and nt represents the total 
amount of food consumption in the NT group.  The body 
weight changes in the dietary restriction groups were similar 
to those in the corresponding 5-FU treated groups.
Water intake (Table 1)
In the 5-FU treated groups, decreases in water intake 
were observed on Days 8 and 13 in the FU15 group and on 
Day 13 in the FU12 and FU18 groups.  These changes were 
not present during the recovery period.  Decreases in water 
intake were also observed on Days 8 and 13 in the R15 and 
R18 groups.  These changes were not present during the 
recovery period.
Hematology (Fig. 3)
In the 5-FU treated groups at the end of the 
administration period, increases in red blood cell count, 
hemoglobin, hematocrit and MCHC and decreases in 
reticulocyte count and total white blood cell count were 
observed in the FU15 and FU18 groups, and a decrease in 
the differential basophil ratio was also observed in the FU18 
group.  All parameters showing changes at the end of the 
administration period in the 5-FU treated groups returned to 
normal levels by the end of the recovery period.  Increases 
were observed in the platelet and reticulocyte counts of the 
FU15 and FU18 groups, and an increase and decrease were 
observed in the neutrophil count and differential lymphocyte 
ratio of the FU18 group, respectively.  In regard to these 
results for the platelet and reticulocyte counts, one animal 
from the FU12 group and 3 animals from the FU15 group 
showed higher values than the group means, and statistically 
significant differences in comparison with the dietary 
restriction groups were observed in the FU18 group.
In the dietary restriction groups at the end of the 
administration period, an increase in hemoglobin and 
decrease in differential monocyte ratio were observed in all 
groups.  Moreover, increases in red blood cell count and 
hematocrit and a decrease in reticulocyte count were 
Table 1. Comparison of Water Intake in the 5-FU Treated and Dietary Restriction Groups with That in the Nontreated Group
Groups NT FU12 FU15 FU18 R12 R15 R18
Administration period
Day 3 (g) 35.9 ± 8.3 28.4 ± 6.1 29.1 ± 5.8 29.6 ± 10.4 32.5 ± 5.0 32.5 ± 3.8 31.7 ± 3.7
Day 8 (g) 35.8 ± 4.5 26.3 ± 11.1 22.3 ± 14.3** 29.7 ± 20.6 30.8 ± 8.0 16.4 ± 1.9** 15.0 ± 2.2**
Day 13 (g) 34.8 ± 5.8 26.2 ± 6.6* 24.0 ± 10.8** 22.6 ± 16.3** 27.6 ± 5.1 16.0 ± 2.4**# 11.6 ± 2.7**
Recovery period
Day 20 (g) 39.5 ± 9.3 36.2 ± 5.8 32.3 ± 5.6 37.4 ± 9.0 41.2 ± 6.3 37.3 ± 5.0 38.0 ± 3.0
Data shown as means ± S.D.
Statistical significance was analyzed using the Dunnett’s test or a Dunnett-type test (*: p<0.05, **: p<0.01) compared with the NT group. 
Moreover, differences in values between the 5-FU treated and corresponding food restricted groups were analyzed by the Student’s t-test or 
Aspin-Welch’s t-test (#: p<0.05).
Table 2. Comparison of Serum EPO Concentration in the 5-FU Treated and Dietary Restriction Groups with That in the Nontreated Group
Groups NT FU12 FU15 FU18 R12 R15 R18
Administration period 2.97 ± 2.55 3.32 ± 5.72 1.35 ± 2.03 0.00 ± 0.00* 0.64 ± 0.77* 0.00 ± 0.00** 0.00 ± 0.00**
(mIU/mL) (Day 14)
Recocery period 6.68 ± 2.06 3.32 ± 2.33 4.35 ± 1.85 8.73 ± 11.67 2.34 ± 1.57** 3.47 ± 1.78* 4.16 ± 2.34
(mIU/mL) (Day 21)
Data shown as means ± S.D.  Values are shown as 0.00 ± 0.00 if EPO was not detected.
Statistical significance was analyzed using the Dunnett’s test or a Dunnett-type test (* and **: p<0.05 and p<0.01, respectively) compared with the NT 
group.  Moreover, differences in values between the 5-FU treated and corresponding food restricted groups were analyzed by the Student’s t-test or Aspin-
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Fig. 3. Comparison of hematology changes with the nontreated group: the red blood cell count (A), hemoglobin (B), hematocrit value (C), 
MCHC (D), reticulocyte counts (E), total white blood cell count (F) and platelets count (G) are shown.  Statistical significance was 
analyzed using Dunnett’s-test or a Dunnett’s-type test (* and **: p<0.05 and p<0.01, respectively) compared with the NT group. 
Moreover, differences in values between the 5-FU treated and food restricted groups were analyzed by the Student’s t-test or Aspin-
Welch’s t-test (# and ##: p<0.05 and p<0.01, respectively).58 Evaluation of Myelotoxicity in Rats
observed in the R15 and R18 groups, and an increase in 
MCHC and decreases in the platelet and total white blood 
cell counts and LUC ratio were observed in the R18 group. 
These changes were not related to food consumption, 
although an increase in red blood cell count was observed in 
the R12 dietary restriction group at the end of the recovery 
period.  All parameters showing changes at the end of the 
administration period also returned to normal levels.
Serum EPO concentrations (Table 2)
In regard to the 5-FU treated groups at the end of the 
administration period, a decrease in the serum EPO 
concentration was only observed in the FU18 group, but the 
concentration returned to a normal level by the end of the 
recovery period.
In regard to the dietary restriction groups at the end of 
the administration period, a decrease in the serum EPO 
concentration was observed in all the dietary restriction 
groups, but the concentration returned to a normal level by 
the end of the recovery period.  An increase in serum EPO 
concentration was also seen in the NT group by the end of 
the recovery period, but the cause of the increase was 
unclear.
Bone marrow examination (Fig. 4, 5)
In the 5-FU treated groups at the end of the 
administration period, abnormal granulocytes (polyploidy: 
frequency 1% or less) were observed in all groups.  This 
change was observed in 2 animals in the FU12 group and 5 
animals each in the FU15 and FU18 groups.  Moreover, 
decreases in the counts of nucleated cells, total erythroblasts, 
total granulocytes and lymphocytes were seen in the FU15 
and FU18 groups, along with an increase in the M/E ratio. 
By the end of the recovery period, all of these parameters 
had returned to normal levels, and no abnormalities were 
seen in any of the groups.
In the dietary restriction groups at the end of the 
administration period, a decrease in the total erythroblast 
count was observed in all groups, and decreases in the 
nucleated cell and lymphocyte counts and an increase in the 
M/E ratio were seen in the R15 and R18 groups.  A decrease 
in the count of total granulocytic series was seen at the end 
of the recovery period; this decrease was even more marked 
than that observed at the end of the administration period, 
and a decrease in the nucleated cell count was observed in 
the R18 group.  There were also decreases in the counts of 
total granulocytic series in all the dietary restriction groups 
and in the differential monocyte and macrophage counts in 
the R18 group.
Organ weight (Table 3)
In regard to the 5-FU treated groups at the end of the 
administration period, there was a decrease in the relative 
weight of the thymus in the FU15 and FU18 groups, and an 
increase in the relative weight of the adrenal in the FU18 
group.  Partial decreases in the absolute weights of other 
organs were also observed, but these changes were 
considered to be related to body weight loss.  In the 5-FU 
treated groups at the end of the recovery period, there was no 
change in the relative weight of the adrenal gland, although 
a further decrease in the weight of the thymus was noted 
compared with the weight at the end of the administration 
period.  These changes bore no relation to the dosage, 
although an increase in the relative weight of the kidney was 
seen in the FU15 group.  A slight decrease in the absolute 
weight of the kidney was also seen at the end of the recovery 
period, and this was considered to be related to body weight 
loss.
In regard the dietary restriction groups at the end of the 
administration period, a decrease in the relative weight of the 
liver was observed in the R15 and R18 groups, and a 
decrease in the relative weight of the thymus was observed in 
the R18 group.  Slight decreases in the absolute weights were 
also observed.  These changes were considered to be related 
to body weight loss.  In the dietary restriction groups at the 
end of the recovery period, none of the changes observed at 
the end of the administration period were still present.  These 
changes were not related to the provided food consumption, 
although there was a decrease in the relative weight of the 
spleen in the R12 group and a decrease in the relative weight 
of the thymus in the R15 group.  Slight decreases in absolute 
weights were also observed.  These changes were considered 
to be related to body weight loss.
Necropsy
In the 5-FU treated groups at the end of the 
administration period, no abnormalities were seen in any of 
the groups, except for adhesion of the ileum to the wall of the 
abdomen in one animal in the FU18 group.
In the dietary restriction groups at the end of the 
administration period or the end of the recovery period, no 
abnormalities were observed in any of the groups.
Histopathology (Fig. 6, 7)
The following changes were observed in the 5-FU 
treated groups.  At the end of the administration period, 
atrophy of the bone marrow was observed in 1 animal of the 
FU12 group, 5 animals of the FU15 group and all animals of 
the FU18 group.  Telangiectasis was observed in 4 animals 
of the FU15 group and 5 animals of the FU18 group.  In 
addition, atrophy of the thymus was observed in 3 animals of 
the FU15 group and all animals of the FU18 group.  Atrophy 
of the white pulp in the spleen was observed in 2 animals of 
the FU18 group.  At the end of the recovery period, 
decreased hematopoiesis in the bone marrow was observed 
in 1 animal of the FU12 group, 3 animals of the FU15 group 
and 2 animals of the FU18 group.  Telangiectasis was not 
observed at the end of the recovery period.  Increased 
extramedullary hematopoiesis in the spleen was also 
observed in 1 animal of the FU12 group, 3 animals of the 
FU15 group and all animals of the FU18 group.
The following changes were observed in the dietary 
restriction groups.  At the end of the administration period, 
decreased hematopoiesis in the bone marrow was observed Miyata, Asanuma, Iwaki et al. 59
Fig. 5. Bone marrow cytology of granulocytes treated with 5-FU.  Representative images of the NT (A), 5-FU treated (B, C) and dietary 
restriction groups (D) are shown.  In the 5-FU treated group at the end of the administration period, polyploidy nuclei were observed in 
granulocytes.  May-Grünwald and Giemsa stain.  Original magnification: ×1,000.  Bar = 10 μm.
Fig. 4. Comparison of bone marrow examination changes with the nontreated group: The nucleated cell count (A), erythroid cell count (B), 
myeloid cell count (C), lymphocyte count (D), monocyte and macrophage counts (E) and M/E ratio (F) are shown.  Statistical significance 
was analyzed using Dunnett’s-test or a Dunnett’s-type test (* and **: p<0.05 and p<0.01, respectively) compared with the NT group. 
Moreover, differences in values between the 5-FU treated and food restricted groups were analyzed by the Student’s t-test or Aspin-
Welch’s t-test (# and ##: p<0.05 and p<0.01, respectively).60 Evaluation of Myelotoxicity in Rats
in 4 animals of the R12 group, 3 animals of the R15 group 
and 3 animals of the R18 group.  Telangiectasis was 
observed in 2 animals of the R15 group and 4 animals of the 
R18 group.  At the end of the recovery period, decreased 
hematopoiesis in the bone marrow was observed in 1 animal 
of the R12 group, and 4 animals of the R15 group and 5 
animals of the R18 group.  Telangiectasis was not observed 
at the end of the recovery period.
No other abnormalities were recognized in any of the 
other organs at any of the examination points in either the 5-
FU treated or dietary restriction groups.
Discussion
Decreases in food consumption and body weight were 
observed at the end of the administration period in the 5-FU 
treated groups.  The body weight changes in the 5-FU treated 
groups were considered to be strongly influenced by the 
decreased food consumption because similar effects were 
observed in two of the study groups (FU15 and FU18 
groups).  The FU15 and FU18 groups showed decreases in 
their reticulocyte, white blood cell, nucleated cell, total 
erythroblastic series and lymphocytes in marrow and an 
uptrend in the marrow M/E ratio.  These changes, however, 
were recognized to have occurred to similar degrees in the 
dietary restriction groups (R15 and R18).  Changes in the 
lymphoid organs due to immunotoxicants appear as a 
decrease in the blood cell count21,22.  Mature granulocytes 
are not significantly affected; however, cytotoxic fungal 
metabolites have been shown to cause a decrease in the 
immature myelocyte count23.  Decreases in blood cell counts 
and bone marrow hypoplasia are well known to be caused by 
5-FU administration18–20.  Drug-induced myelotoxicity has 
been shown in short-term studies24,25.  Ogawa et al.26 and 
Levin et al.5 reported decreases in white blood cell, 
reticulocyte, and nucleated cells or other blood cells in 
marrow counts following dietary restriction in the rat. 
Matsumoto24 reported a reduction in the bone marrow cell 
count with an elevation of the G/E ratio in food-restricted 
rats.  The changes in hematology and results of marrow 
examination in the 5-FU treated group are believed to be 
mostly caused by the decrease in food consumption.  For 
evaluation of chemical toxicity during the administration 
period, it is important to analyze study results in 
consideration of decreases in body weight and food 
consumption.  Decreased food consumption and 
Table 3. Comparison of Organ Weights in the 5-FU Treated and Dietary Restriction Groups with Those in the Nontreated Group
Groups NT FU12 FU15 FU18 R12 R15 R18
Administration period (Day 14)
Absolute organ weight
    Spleen (g) 0.62 ± 0.12 0.50 ± 0.08 0.37 ± 0.10** 0.37 ± 0.08** 0.45 ± 0.07** 0.39 ± 0.04** 0.33 ± 0.07**
    Liver (g) 8.71 ± 0.76 7.13 ± 1.02* 5.71 ± 0.90** 5.50 ± 0.57** 6.87 ± 0.36** 5.32 ± 0.30** 4.73 ± 0.37**
    Kidney (g) 2.39 ± 0.12 2.06 ± 0.30 1.72 ± 0.30** 1.70 ± 0.14** 1.97 ± 0.21** 1.67 ± 0.08** 1.58 ± 0.09**
    Adrenal (mg) 70.5 ± 6.5 62.8 ± 7.2 57.0 ± 9.5 62.8 ± 9.6 52.3 ± 4.8** 53.0 ± 5.4** 47.8 ± 5.7**
    Thymus (g) 0.54 ± 0.07 0.38 ± 0.15 0.17 ± 0.12** 0.16 ± 0.09** 0.47 ± 0.16 0.29 ± 0.03* 0.21 ± 0.06**
Relative organ weight
    Spleen (g%) 0.21 ± 0.03 0.20 ± 0.01 0.18 ± 0.02 0.19 ± 0.02 0.19 ± 0.03 0.18 ± 0.02 0.17 ± 0.04
    Liver (g%) 2.86 ± 0.16 2.89 ± 0.16 2.82 ± 0.16 2.92 ± 0.30 2.80 ± 0.10 2.50 ± 0.17** 2.46 ± 0.21**
    Kidney (g%) 0.78 ± 0.03 0.84 ± 0.06 0.85 ± 0.08 0.90 ± 0.09 0.80 ± 0.08 0.78 ± 0.03 0.82 ± 0.06
    Adrenal (mg%) 23.2 ± 1.7 25.5 ± 2.4 28.2 ± 3.5 34.0 ± 7.4* 21.5 ± 2.1 24.8 ± 2.7 24.8 ± 2.5
    Thymus (g%) 0.18 ± 0.02 0.15 ± 0.05 0.08 ± 0.05** 0.08 ± 0.04** 0.19 ± 0.07 0.14 ± 0.01 0.11 ± 0.03**
    Final body weight (g) 304 ± 19 247 ± 36* 204 ± 38** 187 ± 26** 245 ± 6 213 ± 5** 193 ± 5**
Recovery period (Day 21)
Absolute organ weight
    Spleen (g) 0.71 ± 0.06 0.56 ± 0.08** 0.56 ± 0.08** 0.60 ± 0.05* 0.49 ± 0.07** 0.56 ± 0.07** 0.55 ± 0.07**
    Liver (g) 10.26 ± 1.23 8.37 ± 1.12* 8.13 ± 1.21* 7.67 ± 1.06** 9.23 ± 0.54 8.18 ± 0.13** 7.94 ± 0.38**
    Kidney (g) 2.54 ± 0.31 2.30 ± 0.22 2.12 ± 0.28* 1.94 ± 0.30** 2.20 ± 0.14* 2.11 ± 0.15** 1.97 ± 0.19**
    Adrenal (mg) 69.0 ± 5.5 57.7 ± 10.8* 56.8 ± 6.2* 59.0 ± 5.3 62.7 ± 4.6 57.7 ± 6.2* 55.8 ± 8.4**
    Thymus (g) 0.69 ± 0.16 0.49 ± 0.16 0.45 ± 0.06* 0.33 ± 0.15** 0.50 ± 0.05* 0.39 ± 0.07** 0.42 ± 0.07**
Relative organ weight
    Spleen (g%) 0.21 ± 0.02 0.20 ± 0.03 0.22 ± 0.05 0.24 ± 0.06 0.17 ± 0.03* 0.21 ± 0.03 0.22 ± 0.03
    Liver (g%) 2.95 ± 0.18 2.92 ± 0.21 3.12 ± 0.09 2.97 ± 0.53 3.18 ± 0.14 3.05 ± 0.04 3.16 ± 0.11
    Kidney (g%) 0.73 ± 0.04 0.81 ± 0.04 0.81 ± 0.02* 0.75 ± 0.11 0.76 ± 0.04 0.79 ± 0.05 0.78 ± 0.07
    Adrenal (mg%) 20.0 ± 0.9 20.3 ± 2.2 22.0 ± 3.0 22.8 ± 4.7 21.8 ± 2.0 21.5 ± 2.4 22.2 ± 3.0
    Thymus (g%) 0.20 ± 0.05 0.17 ± 0.04 0.18 ± 0.03 0.12 ± 0.04** 0.17 ± 0.02 0.14 ± 0.03* 0.17 ± 0.03
    Final body weight (g) 347 ± 24 287 ± 35* 261 ± 38** 248 ± 76** 291 ± 7 268 ± 4** 252 ± 8**
Data shown as means ± S.D.
Statistical significance was analyzed using the Dunnett’s test or a Dunnett-type test (* and **: p<0.05 and p<0.01, respectively) compared with the NT 
group.  Moreover, differences in values between the 5-FU treated and corresponding food restricted groups were analyzed by the Student’s t-test or Aspin-
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deteriorating condition are reported to be caused by drug 
cytotoxicity in the lympho-hematopoietic system, which 
contains organs that show rapid cell proliferation, as a result 
of inhibition of cell division by 5-FU27,28.  In the present 
study, many changes in the lympho-hematopoietic system 
were suggested to be caused by decreased food 
consumption.  It is interest to note that the body weight 
changes in the 5-FU treated groups were similar to those in 
the dietary restriction groups, and there were few changes 
that were peculiar to the 5-FU treated groups.  These data are 
expected to be useful for evaluation of compounds that exert 
inhibitory activity against cell division or immunotoxicity in 
screening toxicity studies in the early stages of new drug 
development.
In the present study, the following changes were 
considered to be characteristically associated with 5-FU. 
Decreases in the count of total granulocytic series in bone 
marrow and telangiectasis were more pronounced in the 
FU15 and FU18 groups than in the dietary restriction groups. 
A standard histopathological evaluation is necessary for 
Fig. 6. Bone marrow histopathology at the end of the administration period.  Representative images for the NT (A), 5-FU treated (B) and dietary 
restriction groups (C) are shown.  Decrease of hematopoiesis was observed in the 5-FU treated and dietary restriction groups. 
Telangiectasis was pronounced in the 5-FU treated groups compared with the dietary restriction groups.  H&E.  Magnification: ×35.
Fig. 7. Spleen histopathology at the end of the administration and recovery periods.  The NT (A) and FU18 groups (B) during the administration 
period and FU18 group (C) at the end of the recovery period are shown.  Atrophy of the white pulp of the spleen was observed in the 
FU18 group (B).  Increased extramedullary hematopoiesis was observed in all animals in the FU18 group during the recovery period (C). 
H&E.  Magnification: ×35.62 Evaluation of Myelotoxicity in Rats
evaluation of the organs of the immune system21.  However, 
the above changes were considered to be related to the 
effects of the drug decreasing the blood cell count7 and 
causing blood vessel disorder29 in addition to being 
associated with poor nutrition.  Observation of polyploid 
granulocytes in morphologic observation of the bone 
marrow in the 5-FU treated groups suggests that the changes 
originate from inhibition of DNA synthesis by 5-FU9,10. 
Polyploidy was observed at a low frequency (1% or less) in 
all the 5-FU treated groups, including the FU12 group, 
which exhibited few hematologic changes.  Therefore, based 
on the results, we considered the effects to be related to 5-
FU.  Tewari et al.30 demonstrated ring formation in marrow 
cell nuclei following intraperitoneal administration of 5-FU 
in the rat.  In their report, the morphologic change was 
reversible and was considered to be the earliest sign 
predictive of bone marrow depression by 5-FU.  A 
morphologic change in blood cells, however, is considered 
to be suggestive of myelotoxicity.  In a piperonyl butoxide 
toxicity study, Mitsumori et al.31 reported that the change in 
the compound administration group was caused by a 
decrease in food consumption induced by the compound 
because there was no difference in the observed changes of 
the lympho-hematopoietic system between the compound 
administration and dietary restriction groups.  However, the 
morphology of the blood cells was not examined in their 
report.  In the present study, many of the changes in the 
blood and bone marrow examination parameters observed in 
the 5-FU treated groups were shown to be due to food 
decrease.  When an influence on the lympho-hematopoietic 
system was doubted for some compound, it seemed that 
analysis including morphologic observations of blood cells 
was important.
At the end of the recovery period, increases in the 
reticulocyte and platelets counts were observed more 
frequently in the FU15 and FU18 groups than in the non 5-
FU-treated groups.  Since increased hematopoiesis was 
suggested by these changes, it was thought that the decreased 
hematopoiesis observed during administration of 5-FU 
resulted in active hematopoiesis promotion in the recovery 
period.  We believe that it is necessary to consider the 
possibility a compound may decrease hematopoiesis when 
increased hematopoiesis is observed at the end of the 
recovery period.  Clear histopathologic evidence of 
increased extramedullary hematopoiesis in the spleen was 
observed in the 5-FU treated groups during the recovery 
period.  In the FU12 and FU15 groups, the number of 
animals with pathological changes in the spleen was 
consistent with that of animals with changes in their platelet 
and reticulocyte counts, and such a correlation was also 
noted in the FU18 group.  The changes observed in the 
spleen on histopathologic examination were thought to be 
reflected as changes in the hematologic parameters.
In the present study, dietary restriction appeared to have 
a strong influence on the changes in the counts of 
reticulocytes and bone marrow erythroblasts.  At the end of 
the administration period, the reticulocyte counts decreased 
by about 40% in the R12 group, and by about 80% in the R15 
and R18 groups.  In addition, the bone marrow erythroblast 
count decreased by about 30% in the R12 group, by about 
70% in the R15 group and by about 90% in the R18 group. 
The changes in these parameters in the R12 group are 
obviously slight compared with those in the R15 and R18 
groups, and a slight tendency to a change was recognized in 
other examination values in the R12 group.  In regard to the 
dietary restriction groups at the end of the administration 
period, we believe that the influences on the blood and 
marrow examination values were clearly due to food 
decrease in about 30–40% or more because the dietary 
restriction rate was 25% in R12 and 44% in R15.
In conclusion, we believe that analysis of dietary 
restriction is needed when a decrease in food consumption of 
about 30–40% or more is observed in a rat repeated-dose 
toxicity study.  Careful morphologic observation of 
hemocytes would be helpful in distinguishing drug effects 
from those of dietary restriction in relation to hematologic 
and bone marrow parameters.  In addition, we also 
recommend performance of a recovery test to examine the 
reactive response of hematopoiesis.
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